Inviragen secures $15.5 million to develop needle-free dengue vaccine

FORT COLLINS – Inviragen and PharmaJet announced a five-year, $15.5
million contract from the National Institute of Allergy and Infectious
Diseases to advance the development of a needle-free dengue vaccine.

The award will fund preclinical studies, regulatory filings,
manufacturing and clinical testing of Inviragen’s dengue vaccine,
DENVax, delivered with PharmaJet’s needle-free injection device.

Inviragen got its start in Fort Collins in 2005 with an exclusive
license to develop a dengue vaccine from the Centers for Disease
Control. In 2009, it merged with a Singapore company to continue to
develop vaccines against infectious diseases in…